4 Key Considerations to Win Over Investors
Interview with Glympse Bio CEO Caroline Loew
The simplest ideas often lead to the most elegant solutions.
For example, the body changes when infected with a disease — and those changes are measurable.
This simple truth is the very foundation of Glympse Bio, a biopharmaceutical startup that is revolutionizing disease diagnostics and monitoring.
The company is developing biomarker panels to measure changes in protein activity for a variety of diseases. By analyzing proteins in a simple blood draw, Glympse can identify a disease state and determine whether it is advancing or regressing.
Caroline Loew’s task as President and CEO of Glympse Bio is to ultimately get her company’s technology in the hands of doctors, where it can then make a difference in the lives of patients. But to do so, she has to partner with the right investors to fund her company’s initiatives and she has to work efficiently with regulators to get the technology approved.
An organic chemist by training, Caroline now works at the intersection of science, business, and clinic — a role that’s anything but simple.
“The science can be incredible, absolutely astonishing, and amazing,” Caroline says. “But if it never makes it to a patient, if it never makes it into a physician’s hand so the physician can work with a patient to better their condition, it’s all for nothing.”
In this episode of Medsider, Caroline discusses the importance of being proactive when dealing with regulators. She also shares four key things to consider as you engage with investors.
You May Like These Articles
Medsider Premium
Become a premium member and unlock access to exclusive Medsider benefits.
